Moderna, Inc. (MRNA) FCF Payout Ratio: N/A
The FCF payout ratio for Moderna, Inc. (MRNA) is N/A.
MRNA FCF Payout Ratio Chart
MRNA Average FCF Payout Ratio Chart
MRNA FCF Payout Ratio Metrics
FCF PAYOUT RATIO
N/A
FCF PAYOUT RATIO AVG TTM
1.88%
FCF PAYOUT RATIO AVG 3Y
1.88%
FCF PAYOUT RATIO AVG 5Y
1.88%
FCF PAYOUT RATIO AVG 10Y
1.88%
FCF PAYOUT RATIO AVG 15Y
1.88%
FCF PAYOUT RATIO AVG 20Y
1.88%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Payout Ratio Comparison
FCF Payout Ratio
N/A
Earnings Payout Ratio
N/A
Dividend Yield
N/A
FCF Yield
3.17%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | ($2.06B) | $0 | N/A (Loss) |
| 2024 | ($4.05B) | $0 | N/A (Loss) |
| 2023 | ($3.83B) | $0 | N/A (Loss) |
| 2022 | $4.58B | $0 | 0.0% |
| 2021 | $13.34B | $0 | 0.0% |
| 2020 | $1.96B | $0 | 0.0% |
| 2019 | ($490.52M) | $0 | N/A (Loss) |
| 2018 | ($436.63M) | $0 | N/A (Loss) |
| 2017 | ($389.88M) | $1.48M | N/A (Loss) |
| 2016 | $33.59M | $633,000 | 1.9% |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Moderna, Inc. FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Moderna, Inc. FCF Payout Ratio FAQ
- What is the FCF payout ratio for Moderna, Inc. (MRNA)?
- The FCF payout ratio for MRNA stock is N/A.
- What is the TTM average FCF payout ratio for Moderna, Inc. (MRNA)?
- The TTM average FCF payout ratio for MRNA stock is 1.88%.
- What is the 3Y average FCF payout ratio for Moderna, Inc. (MRNA)?
- The 3Y average FCF payout ratio for MRNA stock is 1.88%.
- What is the 5Y average FCF payout ratio for Moderna, Inc. (MRNA)?
- The 5Y average FCF payout ratio for MRNA stock is 1.88%.
- What is the 10Y average FCF payout ratio for Moderna, Inc. (MRNA)?
- The 10Y average FCF payout ratio for MRNA stock is 1.88%.
- What is the 15Y average FCF payout ratio for Moderna, Inc. (MRNA)?
- The 15Y average FCF payout ratio for MRNA stock is 1.88%.
- What is the 20Y average FCF payout ratio for Moderna, Inc. (MRNA)?
- The 20Y average FCF payout ratio for MRNA stock is 1.88%.
Moderna, Inc. FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2016-12-31 | 1.88% |
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel